Other content in this Stream
Prometic to host key opinion leader meeting on PBI-4050, a novel treatment for Alström Syndrome and promising therapeutic for...
Key Opinion Leader meeting, Friday, September 7th in New York City, on a novel treatment for Alström Syndrome (AS).
Prometic announces the publication of PBI-4050’s antifibrotic activity in liver diseases in journal of pharmacology and...
Prometic receives rare pediatric disease designation from U.S. FDA for small molecule drug candidate PBI-4050
Pivotal data for Prometic’s intravenous Plasminogen replacement therapy to be presented at American Society for Hematology
Prometic receives clearance from the Swedish Medical Products Agency to initiate plasminogen diabetic foot ulcer phase 2 clinical trial
Prometic receives priority review status from Health Canada for Plasminogen (Ryplazim™)